Vice president, general counsel - international markets , IP and corporate litigations | Teva Pharmaceuticals
Orly Alster
Vice president, general counsel - international markets , IP and corporate litigations | Teva Pharmaceuticals
Team size: 10
Looking forward, what technological advancements do you feel will impact the role of in-house legal teams in the future the most?
The Covid-19 experience emphasised the need to establish a global network and develop unique tools to connect better. The advancement of safe technologies that address the need for privileged and secure communication would tremendously impact the legal work and support of in-house counsel.
What would you say are the unique qualities required to be successful as an in-house lawyer in your industry?
An in-house lawyer in the pharmaceutical industry is required to be agile, with a high ability to adapt to changing environments, legislation and changes in strategy. It is essential to have a commercial mindset, with the ability to understand industry drivers in order to provide the best support.
Finally – creative legal thinking is crucial to initiate new opportunities and strategies.
What can law firms do to improve their service to the legal department?
Law firms dealing with pharmaceutical companies must act in various jurisdictions and have a global footprint since the activities in the such industry are usually not limited to one country or jurisdiction.